mycophenolic-acid and Leukemia--Biphenotypic--Acute

mycophenolic-acid has been researched along with Leukemia--Biphenotypic--Acute* in 1 studies

Other Studies

1 other study(ies) available for mycophenolic-acid and Leukemia--Biphenotypic--Acute

Article	Year
Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. Bone marrow transplantation, 2003, Volume: 31, Issue:12 We describe a patient with bcr/abl-positive acute mixed lineage leukemia who successfully underwent transplantation in primary induction failure, using unmanipulated bone marrow from a human leukocyte antigen (HLA)-haploidentical cousin. The tumor burden was successfully reduced by the administration of imatinib mesylate (STI571) before transplantation. As graft-versus-host disease (GVHD) prophylaxis, a combination of tacrolimus and a short course of methotrexate, methylprednisolone, and mycophenolate mofetil was used. Hematopoietic reconstitution was rapid, and acute GVHD was limited to the skin (grade I). The patient is still in complete remission past day +400. This successful case suggests that HLA-haploidentical transplantation using unmanipulated marrow from a distantly related relative can be considered for patients in urgent situations who do not have HLA-identical donors. Topics: Adult; Antineoplastic Agents; Benzamides; Family; Female; Genes, abl; Graft vs Host Disease; Haplotypes; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Methotrexate; Methylprednisolone; Mycophenolic Acid; Pedigree; Piperazines; Pyrimidines; Tacrolimus; Tissue Donors; Transplantation, Homologous	2003

Article

Year

Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin.

Bone marrow transplantation, 2003, Volume: 31, Issue:12

We describe a patient with bcr/abl-positive acute mixed lineage leukemia who successfully underwent transplantation in primary induction failure, using unmanipulated bone marrow from a human leukocyte antigen (HLA)-haploidentical cousin. The tumor burden was successfully reduced by the administration of imatinib mesylate (STI571) before transplantation. As graft-versus-host disease (GVHD) prophylaxis, a combination of tacrolimus and a short course of methotrexate, methylprednisolone, and mycophenolate mofetil was used. Hematopoietic reconstitution was rapid, and acute GVHD was limited to the skin (grade I). The patient is still in complete remission past day +400. This successful case suggests that HLA-haploidentical transplantation using unmanipulated marrow from a distantly related relative can be considered for patients in urgent situations who do not have HLA-identical donors.

Topics: Adult; Antineoplastic Agents; Benzamides; Family; Female; Genes, abl; Graft vs Host Disease; Haplotypes; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Methotrexate; Methylprednisolone; Mycophenolic Acid; Pedigree; Piperazines; Pyrimidines; Tacrolimus; Tissue Donors; Transplantation, Homologous

2003